ProShare Advisors
TSHA icon

ProShare Advisors’s Taysha Gene Therapies TSHA Stock Holding History

ProShare Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Sell
40,817
-3,450
-8% -$20.4K ﹤0.01% 1468
2026
Q1 		$198K Sell
44,267
-8,196
-16% -$38.1K ﹤0.01% 1587
2025
Q4 		$289K Buy
52,463
+6,424
+14% +$31.2K ﹤0.01% 1482
2025
Q3 		$151K Buy
46,039
+2,293
+5% +$6.49K ﹤0.01% 1766
2025
Q2 		$101K Sell
43,746
-3,449
-7% -$7.49K ﹤0.01% 1876
2025
Q1 		$65.6K Sell
47,195
-11,881
-20% -$19.9K ﹤0.01% 1916
2024
Q4 		$102K Buy
59,076
+14,418
+32% +$29.9K ﹤0.01% 2071
2024
Q3 		$89.8K Buy
44,658
+33,113
+287% +$72.7K ﹤0.01% 1899
2024
Q2 		$25.9K Sell
11,545
-1,558
-12% -$4.53K ﹤0.01% 1795
2024
Q1 		$37.6K Buy
13,103
+1,157
+10% +$2.41K ﹤0.01% 1939
2023
Q4 		$21.1K Buy
+11,946
New +$23.8K ﹤0.01% 1916
2022
Q1 		– Sell
-10,368
Closed -$121K – 2301
2021
Q4 		$121K Buy
+10,368
New +$156K ﹤0.01% 2165

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ProShare Advisors's TSHA Position: Q2 2026 in Review

ProShare Advisors reduced its Taysha Gene Therapies (TSHA) stake by 7.8% in Q2 2026, selling an estimated $20.4K and leaving 40,817 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #1468.

ProShare Advisors first reported a position in TSHA in Q4 2021 and has held it in 12 quarters since. The position peaked at $289K in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • ProShare Advisors held 40,817 shares of Taysha Gene Therapies worth $278K as of Q2 2026.
  • ProShare Advisors sold 3,450 Taysha Gene Therapies shares in Q2 2026, an estimated $20.4K.
  • Taysha Gene Therapies made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1468 holding.
  • ProShare Advisors first reported a position in Taysha Gene Therapies in Q4 2021 and has held it in 12 quarters since.
  • ProShare Advisors's Taysha Gene Therapies position peaked at $289K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.